Deceased donor Liver Transplantation for Cholangiocarcinoma

In total more than 21,000 cholangiocarcinomas are diagnosed in the United States each year. The prevalence of cholangiocarcinoma appears to be increasing in the United States and probably in other industrialized countries since data acquisition on [liver cancer](https://www.withpower.com/clinical-trials/liver-cancer) began in the middle of the 20th century. The most common age of diagnosis is 70 yr; less common age groups for cholangiocarcinomas were in the early and middle decades of adulthood. Cholangiocarcinoma is the tenth most common cancer diagnosed in the United States in 2015, and it constitutes the 5th most common cause of cancer-related death in the US in 2015.

CEA in excess of 3 times the upper threshold is a stronger indicator for cholangiocarcinoma than GGT. Other tests are not useful yet in confirming a diagnosis of cholangiocarcinoma.

A combination of surgery, portal vein embolization and neoadjuvant chemotherapy are frequently prescribed; they can alleviate, delay or even avoid surgical resection. For bile duct cancer, in the absence of metastases, resection is the only curative treatment, in which adjuvant chemotherapy is very rarely prescribed.

If diagnosed, the median survival period in patients who have cholangiocarcinoma after surgical resection is 26 months after the initial diagnosis. Cholangiocarcinoma is a rare cancer, and its incidence continues to increase in all countries. cholangiocarcinoma.

Cholangiocarcinoma most commonly occurs in the setting of long-standing inflammatory hepatic disease. Hepatic fibrosis, bile duct obstruction, and biliary cysts are known predisposing factors. This article emphasizes that cholangiocarcinoma should be considered in the differential diagnosis in patients with inflammation, including biliary stent implantation, if this is not contraindicated by tumor burden or symptoms. The pathophysiology of cholangiocarcinoma is not well understood but is an evolving field that is a major area of research.

The surgical treatment of the primary tumor remains the main determinant of DSS in CCA with resection still demonstrating the single greatest prognostic effect in CCA, whereas in other cholangiocarcinomas resection has only a limited and most often no prognostic impact.

Although the majority of clinical trials published in the past half century that utilize LDLT have reported positive results, they have been limited by few patients numbers and short follow-up duration. Thus, further LDLT clinical trials should be undertaken to evaluate long-term outcome in LDLT recipients.

Cholangiocarcinoma is a rare disease with high mortality. The disease is more common in men than women. The average age at the time of diagnosis is 61 years. The 5-year survival rate is 50%. A study by the Korean Working Group for Cirrhosis showed that cholangiocarcinoma was more likely to develop in patients who had a viral infection for a long time and were an alcoholic. There may be a link between cholangiocarcinoma and viral cholangitis. Patients with more than 10 years of liver cirrhosis must be closely monitored for the progression of the disease.

This is the largest study to be done on deceased donor liver transplantation. A significant proportion of recipients with advanced chronic liver diseases can be successfully transplanted using this technique.

Cholangiocarcinoma (CC) is a fatal, yet rapidly developing malignant neoplasm of hepatic biliary ducts (the common bilaterality of primary CCs and metastatic or metastatic/localized CCA occur frequently in both the human population). CCs are common tumours arising in the perihilar region of the common bile duct (CBD) and account for approximately 5-10% of all cancers in the liver.

The current study suggests that deceased donor liver [transplant](https://www.withpower.com/clinical-trials/transplant)ation performed in liver transplant centers is safe and shows a high survival rate in selected patients. Age over 65 years, male gender, and high model for end stage liver disease score are independent risk factors for mortality at least in the 90 days after transplantation.